European treatment targets for drug-resistant TB 'failing to be met'
This article was originally published in Scrip
Tuberculosis (TB) cases have fallen by an average of 5% annually in Europe over the past decade. Worryingly, however, targets set for the treatment of multidrug-resistant TB have not been met, according to new data published by the European Centre for Disease Prevention and Control and the WHO Regional Office for Europe.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.